Alosetron
Alternative Names: GR-68755; GR-68755C; LotronexLatest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Carbolines; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Irritable bowel syndrome
- Discontinued Anxiety disorders; Cognition disorders; Non-ulcer dyspepsia; Schizophrenia
Most Recent Events
- 31 Jul 2011 Prometheus Laboratories has been acquired by Nestle
- 30 Nov 2007 Discontinued - Phase-II for Irritable bowel syndrome in Japan (PO)
- 07 Nov 2007 Alosetron licensed to Prometheus Laboratories in USA